NYSE:LLYPharmaceuticals
Will Strong Q2 Results and Higher 2026 Outlook Change Eli Lilly's (LLY) Narrative?
Eli Lilly and Company recently reported second-quarter 2026 results, with revenue rising to about US$23.0 billion and net income to roughly US$7.10 billion, and raised its full-year 2026 revenue outlook to US$85.0 billion–US$87.0 billion.
At the same time, Lilly is broadening its pipeline and manufacturing base through oncology collaborations, a Breakthrough Therapy designation for KRAS G12C inhibitor olomorasib, and expanded U.S. production capacity for injectable devices used in its...